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Abstract Seven mutant forms of human phosphomannomutase
2 were produced in Escherichia coli and purified. These mutants
had a Vmax of 0.2^50% of the wild enzyme and were unstable.
The least active protein (R141H) bears a very frequent mutation,
which has never been found in the homozygous state whereas the
second least active protein (D188G) corresponds to a mutation
associated with a particularly severe phenotype. We conclude
that total lack of phosphomannomutase 2 is incompatible with
life. Another conclusion is that the elevated residual phospho-
mannomutase activity found in fibroblasts of some patients is
contributed by their mutated phosphomannomutase 2.
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1. Introduction
Carbohydrate-de¢cient glycoprotein (CDG) syndromes are
a series of genetic disorders characterized by a defective N-
glycosylation of serum and cellular proteins [1,2]. The type IA
syndrome (CDG IA), by far the most frequent type, is due to
a de¢ciency in phosphomannomutase (PMM) [3,4], an enzyme
involved in the synthesis of GDP-mannose. This defect results
in abnormal incorporation of mannose into dolichol-pyro-
phosphate oligosaccharide [5] and in a decrease in the number
of oligosaccharides per protein [6].
CDG IA patients bear mutations in the PMM2 gene [7],
which is present on chromosome 16, in a region (p13) previ-
ously identi¢ed as the CDG IA locus [8,9]. A total of 23
di¡erent missense mutations and one single base pair insertion
have been found [7,10]. The most frequent mutation (R141H),
found in 43 of 53 patients, was never observed in the homo-
zygous state, suggesting that homozygosity for this mutation
either is incompatible with life or may lead to a di¡erent,
possibly normal phenotype.
To explain these and other ¢ndings, including the rather
high residual PMM activity found in the ¢broblasts of some
patients [4,10], we have now analyzed the e¡ect of several
mutations on the activity and the stability of human recombi-
nant PMM2.
2. Materials and methods
2.1. Materials
Chemicals were from Sigma or Merck. Phosphomannose isomerase
was from Sigma; other auxiliary enzymes and NADP were from
Boehringer. Mannose 1,6-bisphosphate, prepared as in [3], was puri-
¢ed as in [11]. Extracts of ¢broblasts were prepared as in [3].
2.2. Site-directed mutagenesis
All mutants were constructed as in [12]. Site-directed mutagenesis
was performed by using Pwo DNA polymerase, ‘back-to-back’ mu-
tated primers and the plasmid pBS-PMM2 [13]. To facilitate the se-
lection of the mutated sequences, an additional silent mutation that
introduces or removes a restriction site was systematically added. The
PCR-ampli¢ed plasmids were isolated by electrophoresis in a 1%
agarose gel, puri¢ed with the QiaQuick gel extraction kit and recircu-
larized. The inserts of these mutants were checked by sequencing [14]
to rule out any PCR errors. NdeI-BamHI restriction fragments were
excised and inserted into the expression vector pET3a [15].
2.3. Expression of the recombinant proteins
E. coli BL21(DE3)pLys harboring the expression plasmids were
grown in 0.3 l of M9 medium at 37‡C until A600 reached 0.5^0.6.
The culture was maintained at 4‡C for 20 min before addition of
isopropylthiogalactoside to a ¢nal concentration of 0.4 mM. The in-
cubation was pursued at 18‡C until A600 reached W1.7 (i.e. for about
20 h). Bacterial extracts were prepared and the recombinant enzyme
puri¢ed by a combination of poly(ethylene glycol) precipitation and
chromatography on a DEAE-Sepharose column (1.2U18 cm) [13].
The £ow-through fractions containing wild-type or mutant PMM2
were pooled and concentrated 10-fold by ultra¢ltration in an Amicon
pressure cell equipped with a YM-10 membrane. The enzymes were
stored at 380‡C in the presence of 20 mM HEPES pH 7.1, 2 mg/ml
bovine serum albumin and 1 mM dithiothreitol.
2.4. Enzyme and protein assays
Unless otherwise indicated, PMM was assayed as described [13]
except that the concentration of mannose 1-phosphate was 200 WM
and mannose 1,6-bisphosphate, 10 WM. Protein was measured as in
[16] with bovine gamma-globulin as a standard. PMM assay in ¢bro-
blasts was performed as previously described [4].
2.5. Assay of thermal stability
The mutant and the wild-type PMM2s were incubated at the in-
dicated temperatures and for the indicated times at a concentration of
75 Wg/ml in the presence of 25 mM HEPES pH 7.1, 100 mM KCl,
5 mM MgCl2, 1 mM dithiothreitol and 1 mg/ml bovine serum albu-
min. The PMM activity was then measured and compared to the
initial activity.
3. Results
3.1. Expression and puri¢cation of PMM2 mutants
Preliminary experiments indicated that some of the mutant
proteins were insoluble or unstable when expressed at 37‡C.
Expression was therefore carried out at 18‡C for all proteins
including the wild-type. Extracts of cells prepared 20 h after
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addition of isopropylthiogalactoside displayed PMM activities
ranging between 0.76 nmol/min/mg protein for the R141H
mutant to 938 nmol/min/mg protein for the wild-type enzyme
(Table 1).
The recombinant PMM2 proteins were puri¢ed by poly-
(ethylene glycol) precipitation followed by chromatography
on DEAE-Sepharose at pH 7.1. This procedure allowed us
to separate PMM2, which is not retained by the column
[13], from bacterial PMM, which is only eluted when the
salt gradient is applied [17]. As previously reported for wild-
type PMM2, the protein present in the £ow-through fractions
is puri¢ed to near-homogeneity, as assessed by SDS-PAGE
(not shown). Similar results were obtained for all mutants.
Puri¢cation factors ranged from 40- to 180-fold and the yields
were always higher than 85% indicating that all proteins were
stable at low temperature.
3.2. E¡ect of the mutations on the kinetic properties
Table 1 shows the kinetic properties of the mutants. Five
substitutions decreased the Vmax of PMM2 by 2- to 5-fold. In
one of them (F119L) this change was accompanied by a
marked decrease in the a⁄nity for the substrate and for the
activator mannose 1,6-bisphosphate, whereas in other mu-
tants, these e¡ects were either absent (V129M, V231M) or
modest (R162W); the D65Y showed a 1.7-fold increase in
the a⁄nity for its substrate. The two other substitutions had
a marked e¡ect on the Vmax, which decreased to about 2 and
0.4% of the control value for the D188G and R141H mutant,
respectively. In the case of the D188G mutant, this e¡ect was
partially compensated for by a 3.5-fold increase in the a⁄nity
for the substrate, whereas for the R141H mutant, the decrease
in Vmax was accompanied by an about 10-fold decrease in the
a⁄nity for the substrate and for the activator mannose 1,6-
bisphosphate.
Similar observations were made when the mutations were
introduced into mouse PMM1, the R141H giving rise to the
least active recombinant protein (0.5% of the wild-type value
in crude extracts).
3.3. Thermal stability of PMM2 and mutants
As shown in Fig. 1A, all mutant proteins were signi¢cantly
less stable than the wild-type enzyme. The most unstable one
was the V231M mutant which lost about 50% of its activity in
10 min; at the other extreme were the D188G and R162W
mutant, whose half-lives at 40‡C were about 30 min. All other
mutants showed intermediate behaviors with half-lives of
about 15 min.
The thermal stability was also analyzed by testing the e¡ect
Table 1
Kinetic properties of wild-type and mutant forms of PMM2
Mutation Speci¢c activitya Km for mannose
1-P (WM)
Ka for mannose
1,6-P2 (WM)
extract
(nmol/min/mg prot.)
puri¢ed protein
(Wmol/min/mg prot.) (% of control)
Wild-type 938 35.1 100 18 1.1
D65Y 286 17.7 50.6 11 1.0
F119L 81 8.6 24.5 45 4.9
V129M 355 17.5 50 21 1.1
R141H 0.76 0.14 0.4 165 10.6
R162W 131 6.51 18.6 18 2.1
D188G 9.5 0.66 1.88 5 1.0
V231M 244 13.4 38.5 18 1.1
aThe enzymic activity was assayed with 200 WM mannose 1-phosphate and 10 WM mannose 1,6-bisphosphate, except for the F119L mutant
(200 WM mannose 1-phosphate, 50 WM mannose 1,6-bisphosphate) and R141H mutant (500 WM mannose 1-phosphate, 100 WM mannose 1,6-
bisphosphate). Values shown are the means of three values; S.E.M. were less than 5% of the value to which they refer.
Fig. 1. Thermal stability of wild-type and mutant forms of PMM2.
The enzymes were incubated for the indicated times at 40‡C (A) or
for 30 min at the indicated temperatures (B). The signi¢cance of the
symbols is indicated in (A), except for (X): D65Y; (F), R141H.
Each point represents the mean of three experiments. S.E.M. values
have been omitted for the sake of clarity; they represented 6 10%
of the value to which they refer.
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of 30 min incubations at di¡erent temperatures (Fig. 1B). The
results of such experiments were consistent with those men-
tioned above, the wild-type enzyme being by far the most
stable protein and the V231M mutant, the most unstable
one, with an about 10‡C di¡erence between these two ex-
tremes. All other proteins showed intermediate values with
the same ranking as shown in Fig. 1A.
3.4. PMM activities in ¢broblasts of CDG IA patients
Table 2 shows the PMM activities measured in extracts of
¢broblasts from patients homozygous or heterozygous for
mutations studied in the present work. As previously stressed
[10,18], most of the patients are compound heterozygotes with
the R141H mutation. PMM activities are compared to ‘theo-
retical’ values integrating the e¡ect of the mutations on the
Vmax of the enzyme. Since the R141H mutant is almost inac-
tive, the activity found in extracts of ¢broblasts is virtually
entirely contributed by the other alleles in subjects hetero-
zygous for this mutation.
The less decreased PMM activities were observed in extracts
from patients with the D65Y mutation either in the homo-
zygous state or in the compound heterozygous state with
R141H. Intermediary values were observed with the patients
heterozygous for the V129M, R162W and V231M mutations,
whereas the F119L and most particularly the D188G muta-
tions were associated with the lowest PMM activities. Re-
markably, ¢broblast extracts from patients with the D65Y,
F119L, V129M and V231M mutations had lower PMM val-
ues than expected, whereas this did not appear to be the case
for the R162W and the D188G mutations. The discrepancy
between the calculated and observed value was even more
pronounced in extracts of liver or leukocytes though not
from lymphocytes.
Table 2 also shows that the D188G/R141H phenotype ap-
pears to be associated with a particularly poor vital prognosis
[10].
4. Discussion
We show in this work that all seven CDG IA mutations
that we have studied cause a decrease in the activity and in the
stability of PMM. This entirely con¢rms the view that muta-
tions in the PMM2 gene are responsible for the disease. The
mutation that most a¡ects the Vmax of PMM and its a⁄nity
for mannose 1-phosphate and mannose 1,6-bisphosphate is
R141H. Since, in addition, this mutation destabilizes the en-
zyme, we conclude that it must lead to a virtually inactive
protein in vivo. The fact that this very frequent mutation
was never observed in the homozygous state [10,18], whereas
patients homozygous for other mutations (D65Y, F119L)
have been described [10,19] indicates that a total lack of
PMM2 activity is incompatible with life. This is in keeping
with the fact that the PMM2 isozyme appears to contribute
essentially all of the PMM activity in most tissues [13] and in
¢broblasts [11].
Remarkably, D188G, the second most severe mutation after
R141H appears to be particularly detrimental in vivo, four of
the ¢ve cases with the D188G/R141H genotype having died in
infancy.
Enzymatic assays have shown variable residual PMM ac-
tivity in ¢broblasts of CDG IA patients [4,10]. It appears now
that this residual activity depends on the genotype, being par-
ticularly elevated in the case of patients bearing mutations
that do not a¡ect greatly the activity of the recombinant pro-
tein whereas it is much lower in patients heterozygous for the
severe mutation D188G. In some cases (¢broblasts with mu-
tations D65Y, F119L, V129M, R141H, V231M) but not in
others (D188G, R162W), the activity observed in extracts is
lower than expected from the activity of the recombinant
protein. This is easily explained by the fact that the D188G
and R162W mutants are more stable than the other mutant
proteins.
The fact that some of the mutant proteins still display sub-
stantial activity in ¢broblast extracts suggests that analysis of
this material should be made with caution. It is indeed possi-
ble that some mutations are overlooked because they cause
only a modest decrease in the PMM activity of ¢broblasts.
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